Celebrex scripts see decline

Share this article:
Prescriptions for Pfizer's COX-2 drug Celebrex have dropped 40 percent since last year's withdrawal of Merck's Vioxx, according to a Wednesday report from the investment research company Bernstein. Those numbers could throw a wrench in Pfizer's predicted growth for the upcoming year, analysts said.
"Much of Pfizer's guided 2006 growth is predicated on demand resurgence for COX-2s, this guidance having been given before Bextra's withdrawal," the report said. "Any COX-2 resurgence for Pfizer obviously now must come from Celebrex, which has flattened despite constant physician promotion and the opportunity to capture patients from Vioxx and Bextra withdrawals."
"We view a Celebrex demand resurgence as unlikely," read the report, which rates Pfizer as a "market-perform" or "hold."
A Pfizer spokeswoman told CNNMoney.com that the situation would improve once a warning is added to the Celebrex label.
"Certainly there has been confusion among doctors and patients but this will be clarified by new labeling for all pain relievers that is being negotiated with the FDA at the current time," she said.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.